Growth hormone treatment for Prader-Willi syndrome: A review

Xin Yang1

  • 1Gritscience Biopharmaceuticals Co., Ltd, Life Science Park Road, Changping District, Beijing, China.

Neuropeptides
|August 30, 2020
PubMed

Insights

Growth hormone (GH) treatment improves physical aspects of Prader-Willi Syndrome (PWS) but shows limited effects on cognitive and behavioral issues. Further research is needed to explore GH

Area of Science:

  • Genetics and Developmental Disorders
  • Pediatric Endocrinology

Background:

  • Prader-Willi Syndrome (PWS) is a rare genetic disorder causing hypotonia, developmental delay, cognitive impairment, and hyperphagia leading to obesity.
  • Growth hormone (GH) deficiency is common in PWS, and GH treatment is standard for improving physical development.
  • Existing research confirms GH benefits for motor development, body composition, and linear growth in PWS.

Purpose of the Study:

  • To systematically review recent clinical trials on GH treatment in Prader-Willi Syndrome patients.
  • To emphasize the impact of GH treatment on mental flexibility and behavioral problems in PWS.
  • To discuss concerns regarding the initiation of GH therapy and suggest future research directions.

Main Methods:

  • Systematic analysis of recent clinical trials involving GH treatment for PWS.
  • Focus on studies reporting mental and behavioral outcomes alongside physical changes.
  • Literature review to identify current trends and gaps in PWS research.

Main Results:

  • GH treatment significantly improves motor development, body composition, and linear growth in PWS.
  • Evidence for significant improvements in mental flexibility and behavioral problems remains limited.
  • Concerns regarding the initiation and long-term effects of GH treatment require careful consideration.

Conclusions:

  • GH treatment is beneficial for the physical phenotype of PWS but has minimal impact on cognitive and behavioral aspects.
  • Further basic and clinical research is essential to understand and address the neurological and behavioral challenges in PWS.
  • Future studies should explore novel therapeutic targets and refine GH treatment protocols for PWS.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
671
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
532
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
1.3K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.1K
What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview
78.9K
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
21.9K